We invite you to review the first CIBRN micromodule video from the 2017 season. The video is approximately 12 minutes in length and will provide an overview of discussions surrounding structured questions authored by CIBRN Leaders.
Watch the first CIBRN 2017 micromodules here:
All CIBRN members are invited to take the CIBRN year-end survey here: https://www.surveymonkey.com/r/TD9W88F
Please join the CIBRN Leaders on Tuesday, October 24th at 8:00 pm EST for a one hour, in-depth, cross-discipline discussion of CIBRN 2017 Question #4, Question #5, Question #6 and Question #7 surrounding surrounding the implications of the evolving biosimilar landscape on clinical practice and patient health in Canada.
This webinar is intended for the ALL CIBRN members.
Webinar connection details have been sent to you by email. If you have any questions about the webinar or how to connect, please contact email@example.com.
Prior to the webinar, you are invited to visit the CIBRN community on Sosido to review the questions & responses and to reply with your personal clinical perspectives
Please join the CIBRN Leaders for an in-depth, cross-discipline discussion of CIBRN 2017 Question #1, Question #2 & Question #3 surrounding the implications of the evolving biosimilar landscape on clinical practice and patient health in Canada.
This webinar is intended for the ALL CIBRN members and is scheduled for Thursday, June 8th, 9:00-10:00 pm EST. Webinar connection details will follow by email.
Prior to the webinar, you are invited to visit the CIBRN community on Sosido to review the questions & responses and to reply with your personal clinical perspectives:
The webinar will be recorded and archived for future viewing by the CIBRN community.
If you have any comments or questions, please contact me at your convenience.
If you have never attended an Adobe Connect meeting before:
Test your connection: https://studio7communications.adobeconnect.com/common/help/en/support/meeting_test.htm
Get a quick overview: http://www.adobe.com/products/adobeconnect.html
Source: American Gastroenterological Association, May 25 2017
Gastroenterologists and patients rely on biologics to manage Crohn’s disease and ulcerative colitis. Biosimilar products, which are “highly similar” to the biologic, have begun to be approved by the FDA for such indications. The FDA is now developing a pathway for interchangeable products, which are biosimilars that “may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product” according to Section 351(i) of the Public Health Service Act. Last week, AGA provided the FDA six recommendations in response to the agency’s draft guidance on demonstrating interchangeability focused on measures to enhance patient safety and ensure that physicians, not insurance companies, drive decisions about switching products. Here is a summary of our comments … [view full article]
As we get ready to kick off our second year of the CIBRN learning program, we invite you to review the CIBRN micromodule video from the 2016 season. The video is under 20 minutes in length and will provide an overview of discussions surrounding structured questions authored by CIBRN Leaders.
Watch the 2016 CIBRN micromodules here: